Andere talen Sihuan Pharmaceutical Holdings Group Ltd. Shanghai - Hong Kong Stock Connect

Aandelen

460 BMG8162K1137

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Chinese Regulator Approves Drug Registration for Sihuan Pharmaceutical's Subsidiary's Ticagrelor Orodispersible	07:47
Sihuan Pharmaceutical Holdings Group Ltd. commences an Equity Buyback Plan for 932,999,920 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.	24/06
Sihuan Pharmaceutical Unit Gets Nod for Weight-Loss Drug Application in China	17/06
Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit	13/06
Xuanzhu Biopharmaceutical Co., Ltd. and Livzon Group Livzon Pharmaceutical Factory Reaches an Exclusive Licensing Cooperation on Fadanafil	13/06
Chinese Regulators Approve Sihuan Pharmaceutical’s Drug Registration Application	11/06
Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA	11/06
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	06/06
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	06/06
Sihuan Pharmaceutical, Unit Withdraw Latter's Stock Exchange Bid, Shares Down by Over 3%	27/05
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%	02/05
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government	25/04
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments	29/03
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China	25/03
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring	08/02
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug	23/01
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets	22/01
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3%	10/01
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sihuan Pharmaceutical Holdings Group Ltd. Shanghai - Hong Kong Stock Connect

Aandelen

460

BMG8162K1137

Andere talen

Filters